Cornerstone Planning Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$427K Buy
1,687
+34
+2% +$7.32K 0.05% 114
2026
Q1
$341K Buy
1,653
+16
+1% +$3.55K 0.05% 121
2025
Q4
$358K Buy
1,637
+387
+31% +$88.2K 0.06% 103
2025
Q3
$6.7K Sell
1,250
-444
-26% -$90.4K ﹤0.01% 873
2025
Q2
$336K Sell
1,694
-310
-15% -$57.6K 0.07% 65
2025
Q1
$355K Buy
2,004
+432
+27% +$84K 0.08% 59
2024
Q4
$278K Buy
1,572
+30
+2% +$5.52K 0.07% 59
2024
Q3
$292K Sell
1,542
-841
-35% -$157K 0.08% 57
2024
Q2
$439K Sell
2,383
-1,021
-30% -$169K 0.13% 49
2024
Q1
$557K Sell
3,404
-314
-8% -$54.1K 0.17% 37
2023
Q4
$576K Buy
3,718
+2,895
+352% +$422K 0.19% 39
2023
Q3
$123K Buy
823
+287
+54% +$42.1K 0.05% 106
2023
Q2
$72.2K Buy
+536
New +$78.6K 0.03% 180
2022
Q4
$148K Buy
+997
New +$153K 0.06% 120

Other funds holding ABBV

Cornerstone Planning Group's ABBV Position: Q2 2026 in Review

Cornerstone Planning Group increased its AbbVie (ABBV) stake by 2.1% in Q2 2026, buying an estimated $7.32K and bringing the position to 1,687 shares worth $427K. The position accounts for 0.05% of the portfolio, ranked #114.

Cornerstone Planning Group first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $576K in Q4 2023. 2,841 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Cornerstone Planning Group held 1,687 shares of AbbVie worth $427K as of Q2 2026.
  • Cornerstone Planning Group bought 34 AbbVie shares in Q2 2026, an estimated $7.32K.
  • AbbVie made up 0.05% of Cornerstone Planning Group's portfolio in Q2 2026, its #114 holding.
  • Cornerstone Planning Group first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
  • Cornerstone Planning Group's AbbVie position peaked at $576K in Q4 2023.
  • 2,841 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.